All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Real-world, long-term efficacy of CPX-351, and the impact of MRD, in patients with t-AML or AML-MRC
Bookmark this article
|
A retrospective analysis assessed the real-world efficacy of CPX-351 in 168 adult patients with ND t-AML (n = 47) or AML-MRC (n = 121) and evaluated the impact of MRD on long-term outcomes.1 Results from this trial were published in Blood Advances by Cluzeau et al.1 |
| Key learnings |
| The ORR, CR, and CRi rates were 60%, 53%, and 6%, respectively, and, after a median follow-up of 3 years, the median OS was 13.3 months. |
| The median OS for MRD− vs MRD+ patients was 20.4 months vs 12.9 months (p = 0.03). In multivariate analysis, MRD-positivity was associated with shorter OS (HR, 2.6; 95% CI, 1.2–5.5; p = 0.013). |
| Among patients who underwent allo-HSCT, there was a trend towards improved median OS in MRD− patients vs MRD+ patients (not reached vs 26.0 months; p = 0.06). |
| Results from this analysis confirm the efficacy of CPX-351 in real-world patients with ND t-AML and AML-MRC and highlight the prognostic impact of MRD-negativity in this patient population. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; CI, confidence interval; CR, complete remission; CRi, CR with incomplete hematological recovery; HR, hazard ratio; MRD, measurable residual disease; ORR, overall response rate; OS, overall survival; t-AML, therapy-related acute myeloid leukemia.
- Cluzeau T, Guolo F, Chiche E, et al. Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS. Blood Adv. 2024. Online ahead of print. DOI: 10.1182/bloodadvances.2024014279
Your opinion matters
28 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox